TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33533820
Drug: Late therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late therapy (rehabilitative protocol started 10 weeks later)
Study: 35886189
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) (50 hr, 25 session)
Study: 32067249
Drug: AZD0284 (4-238
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0284 (4-238 mg single dose or 12-100 mg multiple doses)
Study: 35918313
Drug: Suvorexant (SUV);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvorexant (SUV); 10 mg
Study: 35367136
Drug: Mixed allergenic
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed allergenic food powder (MP) containing egg, milk, wheat, soybean, buckwheat, and peanuts, administered in increasing amounts until week 12
Study: 36290823
Drug: Nutritional counseling
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional counseling provided by registered dietitians at least every two weeks during antineoplastic treatment
Study: 34953531
Drug: Oral octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral octreotide (40 mg a day, optional titration to 60 or 80 mg a day)
Study: 34953531
Drug: Injectable somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable somatostatin receptor ligands (iSRLs) at the same dose and interval as before enrolment
Study: 34953531
Drug: Oral octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral octreotide
Study: 34953531
Drug: Injectable somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable somatostatin receptor ligands (iSRLs)
Study: 33612449
Drug: Antifibrinolytics and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifibrinolytics and plasma products (including intravenous immunoglobulin)
Study: 33536271
Drug: Low-dose vs
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vs Standard-dose alteplase
Study: 35398218
Drug: PF-06826647 200
Normalized name: acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-06826647 200 mg
Study: 38279383
Drug: PF-06826647 400
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06826647 400 mg
Study: 34261093
Drug: Long-acting therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting therapy (cabotegravir with rilpivirine, dosed every 4 weeks)
Study: 34261093
Drug: Switch arm
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch arm (transition from current antiretroviral therapy to long-acting therapy)
Study: 34261093
Drug: Long-acting therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting therapy (cabotegravir with rilpivirine)
Study: 35183744
Drug: Topical pHisoHex
Normalized name: Phisohex
DrugBank: Hexachlorophene (DB00756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical pHisoHex (hexachlorophene [1% triclosan; sodium benzoate, 5 mg/mL; and benzyl alcohol, 5 mg/mL])
Study: 34363558
Drug: gilteritinib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: gilteritinib (120 mg/day)
Study: 34363558
Drug: salvage chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: salvage chemotherapy (SC)
Study: 32164886
Drug: Liraglutide (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.8 mg daily or maximum tolerated dose up to 1.8 mg daily)
Study: 34143186
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (Amoxicillin & Clavulanic Acid)
Study: 37545861
Drug: GV1001 1.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: GV1001 1.12 mg
Study: 33771205
Drug: GV1001 0.56
Approvals — FDA: no, EMA: no, PMDA: no
Description: GV1001 0.56 mg
Study: 35063242
Drug: Cornelian cherry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cornelian cherry fruit extract (20 cc/d for 12 weeks)
Study: 35063242
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 cc/d for 12 weeks)
Study: 33109935
Drug: Control participants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control participants received treatment as usual.
Study: 36266930
Drug: Occupational Performance
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational Performance Coaching (OPC) - eight weekly sessions
Study: 35606886
Drug: TF‐CBTp +
Approvals — FDA: no, EMA: no, PMDA: no
Description: TF‐CBTp + treatment as usual (TAU)
Study: 33788296
Drug: MD+LPS (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD+LPS (5 mg/kg)
Study: 33788296
Drug: Control+LPS (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control+LPS (5 mg/kg)
Study: 35606010
Drug: Molnupiravir, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molnupiravir, a novel antiviral medicine aimed at reducing the ability of SARS-CoV-2 to multiply in the body.
Study: 35842120
Drug: Hydronidone 180
Normalized name: Hydronidone
DrugBank: Hydronidone (DB06299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydronidone 180 mg/day
Study: 35842120
Drug: Hydronidone 270
Normalized name: Hydronidone
DrugBank: Hydronidone (DB06299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydronidone 270 mg/day
Study: 35842120
Drug: Hydronidone 360
Normalized name: Hydronidone
DrugBank: Hydronidone (DB06299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydronidone 360 mg/day
Study: 36089558
Drug: Buzzy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buzzy and cold spray
Study: 34726849
Drug: Control treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatments (sponge floss only, ultrasonic device with polyetheretherketone fibre tip coating, and manual scaling with carbon fibre curettes and use of sponge floss)
Study: 34130550
Drug: ω‐3 fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 fish oil (3200 mg/day)
Study: 32889959
Drug: Bioenhanced curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioenhanced curcumin (BEC) 50 mg twice daily
Study: 32575441
Drug: Pomegranate extract
Normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate extract 20 mL (720 mg phenolic compounds) for two weeks
Study: 35761219
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma plus standard therapy (CP + ST)
Study: 35761219
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy alone (ST)
Study: 32183736
Drug: Neoadjuvant laparoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC
Study: 32183736
Drug: Standard R0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard R0 D2 followed by 8 cycles of adjuvant chemotherapy (AC) with oxaliplatin and S-1 (SOX) regimen
Study: 34327732
Drug: Hydroxychloroquine (2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (2400 mg over 5 days)
Study: 34787823
Drug: Weekly dulaglutide
Normalized name: Dulaglutide
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly dulaglutide doses for 4 weeks
Study: 34091608
Drug: Antibiotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics plus bronchoscopic suction every other day
Study: 34091608
Drug: Antibiotics with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics with daily closed-suction
Study: 32660791
Drug: Replacing 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replacing 100 g/day of fried food with non-fried food
Study: 32660791
Drug: Replacing 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replacing 100 g/day of fried protein-rich food
Study: 32660791
Drug: Replacing 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replacing 100 g/day of fried eggs
Study: 32660791
Drug: Replacing 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replacing 100 g/day of fried fish
Study: 34343658
Drug: Daratumumab (Dara)
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab (Dara) with or without standard chemotherapy
Study: 34343658
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (as a control)
Study: 32018062
Drug: Remestemcel-L therapy
Normalized name: remestemcel-L
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remestemcel-L therapy (2 × 10^6 cells/kg twice weekly for 4 weeks)
Study: 32018062
Drug: Remestemcel-L therapy
Normalized name: remestemcel-L
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remestemcel-L therapy
Study: 36103288
Drug: Dermolina-Henna cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermolina-Henna cream
Study: 36103288
Drug: Mometasone cream
Normalized name: mometasone Topical Cream
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone cream
Study: 36235569
Drug: BSG extract-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSG extract-based food supplement
Study: 32158971
Drug: Continuous antibiotic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous antibiotic prophylaxis (CAP) until hydronephrosis resolution or aged 12 months (n=40)
Study: 32802833
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTA) combined with oral finasteride (FNS)
Study: 32860964
Drug: Intermediate-high dose
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-high dose corticosteroids (IHDC)
Study: 32860964
Drug: Pulse dose
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse dose corticosteroids (PDC)
Study: 33577800
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg once daily for 35 days
Study: 33906786
Drug: Radiological evaluation
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiological evaluation of implant position and mechanical axis in LM (+) group
Study: 33906786
Drug: Radiological evaluation
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiological evaluation of implant position and mechanical axis in LM (−) group
Study: 34609303
Drug: Proton-pump-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-pump-based triple therapy (PpTT) for 2 weeks
Study: 34609303
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy for 2 weeks
Study: 34609303
Drug: Proton-pump-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-pump-based triple therapy plus bovine lactoferrin for 2 weeks
Study: 34609303
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy plus bovine lactoferrin for 2 weeks
Study: 36175293
Drug: Romifidine IV
Normalized name: romifidine
DrugBank: Romifidine (DB11543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romifidine IV (80 μg kg–1 premedication, 40 μg kg–1 hour–1 maintenance, 20 μg kg–1 before recovery)
Study: 36175293
Drug: Detomidine IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detomidine IV (15 μg kg–1 premedication, 5 μg kg–1 hour–1 maintenance, 2.5 μg kg–1 before recovery)
Study: 36175293
Drug: Detomidine IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detomidine IV (15 μg kg–1 premedication, 5 μg kg–1 hour–1 maintenance, 5 μg kg–1 before recovery)
Study: 34319275
Drug: Enteric-coated peppermint
Normalized name: Peppermint
DrugBank: Peppermint (DB10984)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated peppermint oil 180 mg 3 times daily
Study: 35943064
Drug: Therapist-assisted Internet-delivered
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-assisted Internet-delivered cognitive therapy for SAD (OSCA)
Study: 33857455
Drug: Staggered group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staggered group (single desynchronised monthly payments)
Study: 33857455
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (monthly synchronised payments)
Study: 32114475
Drug: Extreme hypofractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extreme hypofractionated radiotherapy with stereotactic body radiation therapy to 36.25 Gy/5# (7 to 10 days)
Study: 33068641
Drug: Adrenaline dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline dosing and frequency
Study: 33068641
Drug: Antihistamines and
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamines and corticosteroids
Study: 34238042
Drug: HF with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HF with assertive community treatment (HF-ACT)
Study: 36173415
Drug: Romosozumab 210
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romosozumab 210 mg monthly for 12 months
Study: 33395175
Drug: Topical silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical silver sulfadiazine (SS) cream
Study: 32814589
Drug: Horizontal sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horizontal sperm migration in injection dishes (Group B)
Study: 35980316
Drug: Novel dental
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel dental gel containing 0.454% stannous fluoride and 2.6% EDTA
Study: 32459643
Drug: Blended smoking
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended smoking cessation treatment (n=130)
Study: 32459643
Drug: Face-to-face smoking
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face smoking cessation treatment (n=162)
Study: 32459643
Drug: Face-to-face mode
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face mode of blended treatment
Study: 32459643
Drug: Web mode
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Web mode of blended treatment
Study: 32603632
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioural treatment (ICBT), 8-week treatment
Study: 36107429
Drug: MERM-observed therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MERM-observed therapy (digital medication event reminder monitor); 15-day TB medication supply dispensed with a MERM device.
Study: 36107429
Drug: Standard directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard directly observed therapy (DOT); in-person therapy.
Study: 34195988
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) arm
Study: 32545056
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy intervention
Study: 34102559
Drug: Fortified group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified group 0 (FG0) - 0 mg/100 g bLF
Study: 34102559
Drug: Fortified group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified group 1 (FG1) - 38 mg/100 g bLF
Study: 34102559
Drug: Fortified group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified group 2 (FG2) - 76 mg/100 g bLF
Study: 35304932
Drug: Papaverine (0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine (0.12 mg/ml, 1 ml)
Study: 35304932
Drug: Heparin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (2 units/ml, 1 ml)
Study: 35304932
Drug: Papaverine (0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine (0.12 mg/ml, 1 ml) as rescue treatment
Study: 33596883
Drug: L-Carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Carnitine supplementation (1000 mg)
Study: 32468749
Drug: 1st Generation
Normalized name: CEPHALOSPORIN 1ST GENERATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st Generation Antipsychotics
Study: 32468749
Drug: 2nd Generation
Normalized name: CEPHALOSPORIN 2ND GENERATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2nd Generation Antipsychotics
Study: 35218231
Drug: Foliglurax 10
Normalized name: Foliglurax
DrugBank: Foliglurax (DB15292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foliglurax 10 mg
Study: 35218231
Drug: Foliglurax 30
Normalized name: Foliglurax
DrugBank: Foliglurax (DB15292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foliglurax 30 mg
Study: 35738494
Drug: Macitentan (endothelin-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macitentan (endothelin-1 receptor antagonist)
Study: 33377921
Drug: Nitroglycerin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (5 μg/kg in 0.5 ml)
Study: 32282432
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.5 ml)
Study: 32627599
Drug: Penicillin G/Hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin G/Hydrocortisone (PenGH)
Study: 35123469
Drug: Adjusted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted treatment decision strategy including advice from a treatment algorithm
Study: 33784968
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (ferric derisomaltose (FDI)) 1000 mg
Study: 33784968
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (ferric derisomaltose (FDI))
Study: 35293508
Drug: G1: 1100
Approvals — FDA: no, EMA: no, PMDA: no
Description: G1: 1100 μg F/g, pH 4.5 (n = 76)
Study: 35293508
Drug: G2: 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: G2: 750 μg F/g, pH 4.5 (n = 74)
Study: 35293508
Drug: G3: 1100
Approvals — FDA: no, EMA: no, PMDA: no
Description: G3: 1100 μg F/g, pH 7.0 (n = 78)
Study: 33704351
Drug: Aflibercept (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept (2 mg/0.05 mL at baseline, 4 weeks, and 8 weeks, as needed from 12 weeks onward)
Study: 34000834
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (2 grams intravenous)
Study: 34000834
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching intravenous)
Study: 33234846
Drug: Nivolumab 1
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for 4 cycles followed by nivolumab 3 mg/kg every 2 weeks until progression or unacceptable toxicity or a maximum of 48 weeks.
Study: 33576394
Drug: Informational handout
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Informational handout detailing U.S. Food and Drug Administration‐recommended ways to properly dispose of leftover opioids (n=188)
Study: 33576394
Drug: Informational handout
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Informational handout and a drug disposal kit with instructions on its use (n=170)
Study: 32441668
Drug: Fenugreek 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenugreek 400 mg/d
Study: 32441668
Drug: Fenugreek 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenugreek 500 mg/d
Study: 35138350
Drug: Missing one
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Missing one or more recommended medications
Study: 36388925
Drug: Ulmus macrocarpa
Normalized name: Ulmus rubra pollen
DrugBank: Ulmus rubra pollen (DB10985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulmus macrocarpa Hance extract (UME) 500 mg (two capsules per day)
Study: 36388925
Drug: Placebo (cornstarch,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cornstarch, two capsules per day)
Study: 36168678
Drug: Gore-Tex® thyroplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gore-Tex® thyroplasty with prior injection laryngoplasty (IL)
Study: 36168678
Drug: Gore-Tex® thyroplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gore-Tex® thyroplasty without prior injection laryngoplasty (IL)
Study: 32862469
Drug: Intravenous eptinezumab
Normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous eptinezumab 100 mg
Study: 32862469
Drug: Intravenous eptinezumab
Normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous eptinezumab 300 mg
Study: 33741668
Drug: Structured supervised
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured supervised exercise training consisting of three weekly exercise sessions
Study: 32301053
Drug: Intradialytic combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradialytic combined exercise (24-week, three times weekly, moderate-intensity)
Study: 32506309
Drug: FDC of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC of IBU/APAP 200 mg/500 mg
Study: 32506309
Drug: FDC of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC of IBU/APAP 250 mg/500 mg
Study: 32506309
Drug: FDC of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC of IBU/APAP 300 mg/500 mg
Study: 35166009
Drug: Empagliflozin (10/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10/25 mg/day)
Study: 33130153
Drug: Tailored cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored cognitive behavioral therapy (ADAPT) plus medical treatment as usual
Study: 33130153
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment as usual only
Study: 35909479
Drug: Posterior auricular
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior auricular injection (retroauricular group)
Study: 35909479
Drug: Tympanum injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tympanum injection (tympanic group)
Study: 32314939
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (GA) with patient‐controlled intravenous analgesia